Skip to content

Australian-invented drug technology used for treatment of anxiety disorders significantly reduces stress hormone response: Phase 2a clinical trial results

By Gold Cross - November 17, 2023

Clinical trial
This article is only available to ITK members and is restricted for Pharmacists. Please or Register as a Pharmacist to read the content.
Share this article:
Article tags

Articles you might be interested in

, ,

Oyster ‘blood’ holds promise for combating drug-resistant superbugs: new research

Gold Cross | January 21, 2025
Pharmacist Only

Cannabis importing 101

Gold Cross | January 14, 2025
, , ,

Surveillance tech is changing our behaviour – and our brains

Gold Cross | January 14, 2025
,

Embracing your pharmacy as a business

Gold Cross | December 17, 2024
BD Rowa automation gives you back 6 hours in your day

Latest Posts

New link revealed between hypertension and the gut
Gold Cross | January 30, 2025
Pharmacist Only
Final Call: APP2025 Early Bird pricing ends tomorrow!
Gold Cross | January 30, 2025
Pharmacist Only
Medical professionals fear cases of B6 toxicity are under-reported
Gold Cross | January 28, 2025

Featured Posts

Nurturing brain health for business owners
Gold Cross | January 28, 2025
How genuine conversations impact high performing teams
Gold Cross | December 10, 2024
Protecting your pharmacy: online reviews and defamation explained
Gold Cross | December 3, 2024

Tags

Scroll To Top